NVS Quote, Financials, Valuation and Earnings

GSK PLC has a net margin of 26.48% compared to Novartis AG's net margin of 21.61%. Novartis AG's return on equity of 30.96% beat GSK PLC's return on equity of 23.08%.

Novartis AG has a consensus price target of $112.37, signalling upside risk potential of 2.03%. On the other hand GSK PLC has an analysts' consensus of $41.59 which suggests that it could grow by 12.81%. Given that GSK PLC has higher upside potential than Novartis AG, analysts believe GSK PLC is more attractive than Novartis AG.

Novartis AG has a beta of 0.603, which suggesting that the stock is 39.726% less volatile than S&P 500. In comparison GSK PLC has a beta of 0.539, suggesting its less volatile than the S&P 500 by 46.147%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.63%. GSK PLC offers a yield of 4.22% to investors and pays a quarterly dividend of $0.40 per share. Novartis AG pays 63.85% of its earnings as a dividend. GSK PLC pays out 94.91% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than GSK PLC quarterly revenues of $9.5B. Novartis AG's net income of $3.6B is higher than GSK PLC's net income of $2B. Notably, Novartis AG's price-to-earnings ratio is 17.23x while GSK PLC's PE ratio is 19.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.17x versus 1.90x for GSK PLC. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 26.48% compared to Novartis AG's net margin of 50.24%. Novartis AG's return on equity of 30.96% beat Johnson & Johnson's return on equity of 30.18%.

Novartis AG has a consensus price target of $112.37, signalling upside risk potential of 2.03%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 9.33%. Given that Johnson & Johnson has higher upside potential than Novartis AG, analysts believe Johnson & Johnson is more attractive than Novartis AG.

Novartis AG has a beta of 0.603, which suggesting that the stock is 39.726% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.63%. Johnson & Johnson offers a yield of 3.19% to investors and pays a quarterly dividend of $1.24 per share. Novartis AG pays 63.85% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Novartis AG's net income of $3.6B is lower than Johnson & Johnson's net income of $11B. Notably, Novartis AG's price-to-earnings ratio is 17.23x while Johnson & Johnson's PE ratio is 17.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.17x versus 4.23x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Regulus Therapeutics has a net margin of 26.48% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 30.96% beat Regulus Therapeutics's return on equity of --.

Novartis AG has a consensus price target of $112.37, signalling upside risk potential of 2.03%. On the other hand Regulus Therapeutics has an analysts' consensus of $8.80 which suggests that it could grow by 12.1%. Given that Regulus Therapeutics has higher upside potential than Novartis AG, analysts believe Regulus Therapeutics is more attractive than Novartis AG.

Novartis AG has a beta of 0.603, which suggesting that the stock is 39.726% less volatile than S&P 500. In comparison Regulus Therapeutics has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.604%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.63%. Regulus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 63.85% of its earnings as a dividend. Regulus Therapeutics pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Regulus Therapeutics quarterly revenues of --. Novartis AG's net income of $3.6B is higher than Regulus Therapeutics's net income of -$12.8M. Notably, Novartis AG's price-to-earnings ratio is 17.23x while Regulus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.17x versus -- for Regulus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of 26.48% compared to Novartis AG's net margin of 17.65%. Novartis AG's return on equity of 30.96% beat Sanofi SA's return on equity of 8.47%.

Novartis AG has a consensus price target of $112.37, signalling upside risk potential of 2.03%. On the other hand Sanofi SA has an analysts' consensus of $64.64 which suggests that it could grow by 23.99%. Given that Sanofi SA has higher upside potential than Novartis AG, analysts believe Sanofi SA is more attractive than Novartis AG.

Novartis AG has a beta of 0.603, which suggesting that the stock is 39.726% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.546, suggesting its less volatile than the S&P 500 by 45.374%.

Novartis AG has a quarterly dividend of $3.99 per share corresponding to a yield of 3.63%. Sanofi SA offers a yield of 7.55% to investors and pays a quarterly dividend of $2.21 per share. Novartis AG pays 63.85% of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.6B, which are larger than Sanofi SA quarterly revenues of $11.2B. Novartis AG's net income of $3.6B is higher than Sanofi SA's net income of $2B. Notably, Novartis AG's price-to-earnings ratio is 17.23x while Sanofi SA's PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 4.17x versus 2.68x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.